Abstract:Background: The global burden of non-alcoholic fatty liver disease (NAFLD) is growing, but its subsequent health consequences have not been thoroughly examined. We performed phenome-wide Mendelian randomization and disease-trajectory analyses to comprehensively assess the health outcomes of NAFLD.Methods: PheWAS analyses were conducted to map the associations of NAFLD with a broad range of phenotypes among 475,554 European in UK Biobank. Disease-trajectory and comorbidity analyses were applied to visualize the sequential patterns of multiple comorbidities related to the occurrence of NAFLD. The associations jointly verified by observational and polygenic PheWAS analyses were further replicated by two-sample MR analysis using data from the FinnGen study and international consortia.Findings: PheWAS analyses including 1,172 disease outcomes revealed the associations of NAFLD diagnosis (n=9,035) with intrahepatic (e.g., cirrhosis, liver abscess and liver cancer) and extrahepatic diseases, including circulatory diseases (i.e., various cardiac diseases, hypertension and cerebrovascular diseases), metabolic diseases (i.e., hyperlipidemia and diabetes mellitus), genitourinary system diseases (i.e., renal failure), neurological disorders (i.e., dementias and Alzheimer's disease), gastrointestinal diseases (i.e., gastritis, duodenitis and ulcerative colitis, stomach cancer and other malignant digestive neoplasms) and hematologic diseases (i.e., iron deficiency anemia and thrombocytopenia). Disease-trajectory and comorbidity network analyses identified 3 major extrahepatic comorbidities clusters related to NAFLD, mainly in cardiovascular, metabolic, and inflammatory diseases. Two-sample MR analyses supported the causal associations between NAFLD and the risk of several intrahepatic disorders, metabolic diseases, cardio-cerebro-vascular disease and ascites, but found no associations with neurological diseases (i.e., dementia).Interpretation: A prior diagnosis of NAFLD was associated with an increased risk of various extrahepatic diseases of circulatory, metabolic, genitourinary, gastrointestinal and possibly neurological systems. Three major sequential patterns of comorbidities related to NAFLD were identified, mainly in cardiovascular, metabolic and inflammatory diseases, contributing to development of combination interventions targeting distinct pathways for the health promotion among NAFLD patients.Funding: XL: the Natural Science Fund for Distinguished Young Scholars of Zhejiang Province (LR22H260001) and the National Nature Science Foundation of China (N0. 82204019); SCL: the Swedish Heart-Lung Foundation (Hjärt-Lungfonden, 20210351), the Swedish Research Council (Vetenskapsrådet, 2019-00977), and the Swedish Cancer Society (Cancerfonden).Declaration of Interest: All authors report no potential conflicts of interest.Ethical Approval: Ethical approval was granted by the UK Biobank by the North West-Haydock Research Ethics Committee (REC reference: 16/NW/0274).

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016â€“2030

Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the Period 2016-2030.

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

Multisystem Health Comorbidity Networks of Nonalcoholic Fatty Liver Disease: Phenome-Wide Mendelian Randomization and Disease-Trajectory Analyses

P21 Multisystem Health Consequences of Nonalcoholic Fatty Liver Disease: Phenome-Wide Mendelian Randomization and Disease-Trajectory Analyses

Disease Burden of Chronic Hepatitis B and Complications in China from 2006 to 2050: an Individual-Based Modeling Study

Worldwide long-term trends in the incidence of nonalcoholic fatty liver disease during 1990–2019: A joinpoint and age-period-cohort analysis

Sex-specific Metabolic Risk Factors and Their Trajectories Towards the Non-Alcoholic Fatty Liver Disease Incidence.

Global Burden of Nonalcoholic Fatty Liver Disease, 1990 to 2019 Findings From the Global Burden of Disease Study 2019

Burden of Liver Complications Related to Non‐alcoholic Fatty Liver Disease in China from 2005 to 2019: Observations from the Global Burden of Disease Study, 2019

Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

The Burden of Chronic Hepatitis C in China from 2004 to 2050: an Individual‐Based Modeling Study

The Burden of Liver Cirrhosis and Underlying Etiologies: Results from the Global Burden of Disease Study 2019

2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis

The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease

Global burden of nonalcoholic steatohepatitis-related liver cancer, 1990–2019: a systematic analysis for the GBD 2019

Global Trend of Aetiology-Based Primary Liver Cancer Incidence from 1990 to 2030: a Modelling Study

A unified framework for prediction of liver steatosis dynamics in response to different diet and drug interventions

Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world

Global burden of adult non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has been steadily increasing over the past decades and is expected to persist in the future